{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T04:27:20Z","timestamp":1788582440593,"version":"build-2803163510"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100006769","name":"Russian Science Foundation","doi-asserted-by":"publisher","award":["18-75-10073"],"award-info":[{"award-number":["18-75-10073"]}],"id":[{"id":"10.13039\/501100006769","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gene"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.gene.2020.144513","type":"journal-article","created":{"date-parts":[[2020,2,26]],"date-time":"2020-02-26T12:10:04Z","timestamp":1582719004000},"page":"144513","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Effects of plasma concentration of micro-RNA Mir-27b and CYP3A4*22 on equilibrium concentration of alprazolam in patients with anxiety disorders comorbid with alcohol use disorder"],"prefix":"10.1016","volume":"739","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0607-4812","authenticated-orcid":false,"given":"M.S.","family":"Zastrozhin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.Yu.","family":"Skryabin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.V.","family":"Smirnov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.E.","family":"Petukhov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.P.","family":"Pankratenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.K.","family":"Zastrozhina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.A.","family":"Grishina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.A.","family":"Ryzhikova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.V.","family":"Bure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9379-4214","authenticated-orcid":false,"given":"P.A.","family":"Golovinskii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.G.","family":"Koporov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.A.","family":"Bryun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.A.","family":"Sychev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.gene.2020.144513_b0005","doi-asserted-by":"crossref","first-page":"93","DOI":"10.31887\/DCNS.2017.19.2\/bbandelow","article-title":"Treatment of anxiety disorders","volume":"19","author":"Bandelow","year":"2017","journal-title":"Dialogues Clin. Neurosci."},{"issue":"1\u20133","key":"10.1016\/j.gene.2020.144513_b0010","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.jad.2010.12.014","article-title":"Comorbidity and risk indicators for alcohol use disorders among persons with anxiety and\/or depressive disorders: findings from the Netherlands Study of Depression and Anxiety (NESDA)","volume":"131","author":"Boschloo","year":"2011","journal-title":"J. Affect Disord."},{"issue":"7","key":"10.1016\/j.gene.2020.144513_b0015","first-page":"28","article-title":"The clinical global impressions scale: applying a research tool in clinical practice","volume":"4","author":"Busner","year":"2007","journal-title":"Psychiatry (Edgmont)."},{"issue":"6","key":"10.1016\/j.gene.2020.144513_b0020","doi-asserted-by":"crossref","first-page":"e00192","DOI":"10.1002\/prp2.192","article-title":"miRNA-27b levels are associated with CYP3A activity in vitro and in vivo","volume":"3","author":"Ekstr\u00f6m","year":"2015","journal-title":"Pharmacol Res Perspect."},{"issue":"8","key":"10.1016\/j.gene.2020.144513_b0025","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1111\/j.1530-0277.1999.tb04349.x","article-title":"Psychometric properties of the Penn Alcohol Craving Scale","volume":"N23","author":"Flannery","year":"1999","journal-title":"Alcohol Clin Exp Res."},{"key":"10.1016\/j.gene.2020.144513_b0030","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.2044-8341.1959.tb00467.x","article-title":"The assessment of anxiety states by rating","volume":"32","author":"Hamilton","year":"1959","journal-title":"Br. J. Med. Psychol."},{"issue":"1\u20132","key":"10.1016\/j.gene.2020.144513_b0035","first-page":"1","article-title":"The problems of long-term treatment with benzodiazepines and related substances","volume":"112","author":"Janhsen","year":"2015","journal-title":"Dtsch Arztebl Int."},{"key":"10.1016\/j.gene.2020.144513_b0040","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3389\/fgene.2013.00012","article-title":"Pharmacogenomics of Cytochrome P450 3A4: Recent Progress Toward the \u201cMissing Heritability\u201d Problem","volume":"4","author":"Klein","year":"2013","journal-title":"Front Genet."},{"issue":"6","key":"10.1016\/j.gene.2020.144513_b0045","doi-asserted-by":"crossref","first-page":"479","DOI":"10.4196\/kjpp.2013.17.6.479","article-title":"Screening of Genetic Polymorphisms of CYP3A4 and CYP3A5 Genes","volume":"17","author":"Lee","year":"2013","journal-title":"Korean J. Physiol. Pharmacol."},{"key":"10.1016\/j.gene.2020.144513_b0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0447.1987.tb10566.x","article-title":"The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients","volume":"334","author":"Lingjaerde","year":"1987","journal-title":"Acta Psychiatr. Scand. Suppl."},{"issue":"1","key":"10.1016\/j.gene.2020.144513_b0055","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jchromb.2009.11.023","article-title":"Quantification of cortisol and 6 beta-hydroxycortisol in human urine by LC-MS\/MS, and gender-specific evaluation of the metabolic ratio as biomarker of CYP3A activity","volume":"878","author":"Lutz","year":"2010","journal-title":"J Chromatogr. B Analyt. Technol. Biomed Life Sci."},{"issue":"8","key":"10.1016\/j.gene.2020.144513_b0060","doi-asserted-by":"crossref","first-page":"827","DOI":"10.2174\/138920008786049258","article-title":"Benzodiazepine metabolism: an analytical perspective","volume":"9","author":"Mandrioli","year":"2008","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.gene.2020.144513_b0065","unstructured":"Ron HN van Schaik. Dose Adjustments Based on Pharmacogenetics of CYP450 Enzymes. EJIFCC. 2008 Apr; 19(1): 42\u201347. Published online 2008 Apr 3."},{"issue":"1","key":"10.1016\/j.gene.2020.144513_b0070","first-page":"34","article-title":"Guidelines for the pharmacological management of depression","volume":"59","author":"Shiv","year":"2017","journal-title":"Indian J. Psychiatry."},{"issue":"3","key":"10.1016\/j.gene.2020.144513_b0075","first-page":"129","article-title":"Genotyping and phenotyping of CYP2D6 and CYP3A isoenzymes in patients with alcohol use disorder: correlation with haloperidol plasma concentration","volume":"32","author":"Sychev","year":"2017","journal-title":"Drug. Metab. Pers. Ther."},{"issue":"5684","key":"10.1016\/j.gene.2020.144513_b0080","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1126\/science.1099736","article-title":"Crystal structures of human cytochrome P450 3A4 bound to metyrapone and progesterone","volume":"305","author":"Williams","year":"2004","journal-title":"Science."},{"issue":"4","key":"10.1016\/j.gene.2020.144513_b0085","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1515\/dmpt-2018-0019","article-title":"Effects of CYP2C19*17 polymorphisms on the efficacy and safety of bromodigyrochlorophenylbenzodiazepine in patients with anxiety disorder and comorbid alcohol use disorder","volume":"33","author":"Zastrozhin","year":"2018","journal-title":"Drug. Metab. Pers. Ther."},{"key":"10.1016\/j.gene.2020.144513_b0090","first-page":"1","article-title":"The influence of CYP3A5 polymorphisms on haloperidol treatment in patients with alcohol addiction","volume":"11","author":"Zastrozhin","year":"2017","journal-title":"Pharmgenomics Pers Med."},{"issue":"6","key":"10.1016\/j.gene.2020.144513_b0095","doi-asserted-by":"crossref","first-page":"e2677","DOI":"10.1002\/hup.2677","article-title":"Using a personalized clinical decision support system for bromdihydrochlorphenylbenzodiazepine dosing in patients with anxiety disorders based on the pharmacogenomic markers","volume":"33","author":"Zastrozhin","year":"2018","journal-title":"Hum Psychopharmacol."},{"issue":"6","key":"10.1016\/j.gene.2020.144513_b0100","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","article-title":"The hospital anxiety and depression scale","volume":"67","author":"Zigmond","year":"1983","journal-title":"Acta Psychiatr. Scand."}],"container-title":["Gene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378111920301827?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378111920301827?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T22:05:17Z","timestamp":1778537117000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378111920301827"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":20,"alternative-id":["S0378111920301827"],"URL":"https:\/\/doi.org\/10.1016\/j.gene.2020.144513","relation":{},"ISSN":["0378-1119"],"issn-type":[{"value":"0378-1119","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of plasma concentration of micro-RNA Mir-27b and CYP3A4*22 on equilibrium concentration of alprazolam in patients with anxiety disorders comorbid with alcohol use disorder","name":"articletitle","label":"Article Title"},{"value":"Gene","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gene.2020.144513","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"144513"}}